Shilpa Medicare has informed that US FDA has concluded Remote Record Review of Shilpa Medicare, Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th November 2021. Shilpa Medicare, Unit III, R&D facility is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.
The above information is a part of company’s filings submitted to BSE.
